Enrichment analysis of potential targets bound by the AML1/ETO-AML1 complex with gene sets associated with AML1/ETO regulation
| Gene set . | Number in the gene set . | Potential targets bound by the AML1/ETO-AML1complex . | |||
|---|---|---|---|---|---|
| Number in the gene set . | Fold enrichment . | Z-score . | P value . | ||
| Kasumi-1_AML1/ETO_down | 407 | 232 | 2.50 | 14.48 | 2.87E−35 |
| Kasumi-1_AML1/ETO_up | 359 | 166 | 2.03 | 9.32 | 4.78E−17 |
| SKNO-1_AML1/ETO_down | 660 | 255 | 2.61 | 15.92 | 1.05E−41 |
| SKNO-1_AML1/ETO_up | 700 | 200 | 1.93 | 9.45 | 6.33E−18 |
| AML-M2_ AML1/ETO_down | 544 | 267 | 2.00 | 11.59 | 1.02E−25 |
| AML-M2_AML1/ETO_up | 416 | 196 | 1.92 | 9.33 | 1.71E−17 |
| Gene set . | Number in the gene set . | Potential targets bound by the AML1/ETO-AML1complex . | |||
|---|---|---|---|---|---|
| Number in the gene set . | Fold enrichment . | Z-score . | P value . | ||
| Kasumi-1_AML1/ETO_down | 407 | 232 | 2.50 | 14.48 | 2.87E−35 |
| Kasumi-1_AML1/ETO_up | 359 | 166 | 2.03 | 9.32 | 4.78E−17 |
| SKNO-1_AML1/ETO_down | 660 | 255 | 2.61 | 15.92 | 1.05E−41 |
| SKNO-1_AML1/ETO_up | 700 | 200 | 1.93 | 9.45 | 6.33E−18 |
| AML-M2_ AML1/ETO_down | 544 | 267 | 2.00 | 11.59 | 1.02E−25 |
| AML-M2_AML1/ETO_up | 416 | 196 | 1.92 | 9.33 | 1.71E−17 |
AML-M2_AML1/ETO_down and AML-M2_AML1/ETO_up, AML1/ETO-downregulated and AML1/ETO-upregulated gene signatures in AML1/ETO-positive AML-M2 patients compared with AML1/ETO-negative AML-M2 patients, respectively; Kasumi-1_AML1/ETO_down or SKNO-1_AML1/ETO_down, AML1/ETO-repressed genes that were upregulated after AML1/ETO knockdown in Kasumi-1 or SKNO-1 cells; Kasumi-1_AML1/ETO_up or SKNO-1_AML1/ETO_up, AML1/ETO-activated genes that were downregulated after AML1/ETO knockdown in Kasumi-1 or SKNO-1 cells.